Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESSICA R BERNSTEIN

Allopathic & Osteopathic Physicians Dermatology

NPI
1376858415
CMS profile
153554
Location
DELRAY BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,080.43

58 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,080.43 58

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESSICA R BERNSTEIN

NPI 1376858415 · CMS profile ID 153554

Allopathic & Osteopathic Physicians / Dermatology

DELRAY BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376858415?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESSICA R BERNSTEIN, NPI 1376858415, CMS profile ID 153554. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376858415?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JESSICA R BERNSTEIN, NPI 1376858415, CMS profile ID 153554. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376858415?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JESSICA R BERNSTEIN, NPI 1376858415, CMS profile ID 153554, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1376858415?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

58 matching records · $1,080.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 58 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–58 of 58.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $16.2102/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818567581 CMS
Almirall LLC $22.2302/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819691619 CMS
Janssen Biotech, Inc. $17.7302/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788174445 CMS
AbbVie Inc. $5.9201/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794051277 CMS
AbbVie Inc. $15.2501/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794051273 CMS
GENZYME CORPORATION $20.6501/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843639997 CMS
AbbVie Inc. $18.6401/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794051269 CMS
PFIZER INC. $16.0501/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832717093 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,976.15 68
PY2020 $464.48 29
PY2021 $1,080.43 58
PY2022 $571.28 18
PY2023 $270.43 8
PY2024 $586.41 10
PY2025 $648.29 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $521,857.22 52
PY2024 Principal investigator $53,624.36 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $53,873.00 12/22/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137269
Principal investigator 1 SANOFI US SERVICES INC. $47,356.40 12/15/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137276
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 11/27/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192143010
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 11/27/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192143020
Principal investigator 1 GlaxoSmithKline, LLC. $1,400.00 11/27/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192148073
Principal investigator 1 SANOFI US SERVICES INC. $63,261.10 11/17/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137205
Principal investigator 1 GlaxoSmithKline, LLC. $120.00 10/20/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192144473
Principal investigator 1 SANOFI US SERVICES INC. $500.00 10/20/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137173
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 10/16/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192144452
Principal investigator 1 SANOFI US SERVICES INC. $560.00 10/14/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137167
Principal investigator 1 SANOFI US SERVICES INC. $3,400.00 10/14/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137170
Principal investigator 1 SANOFI US SERVICES INC. $1,765.00 10/06/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137151
Principal investigator 1 SANOFI US SERVICES INC. $3,140.00 09/22/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137118
Principal investigator 1 SANOFI US SERVICES INC. $39,175.50 09/22/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137133
Principal investigator 1 SANOFI US SERVICES INC. $990.00 09/08/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137664
Principal investigator 1 GlaxoSmithKline, LLC. $1,080.00 09/04/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192146787
Principal investigator 1 GlaxoSmithKline, LLC. $1,400.00 09/04/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192146805
Principal investigator 1 SANOFI US SERVICES INC. $5,493.50 09/03/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137094
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 08/27/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192143013
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 08/27/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192143030
Principal investigator 1 SANOFI US SERVICES INC. $26,486.60 08/25/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137106
Principal investigator 1 SANOFI US SERVICES INC. $3,405.75 08/18/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137649
Principal investigator 1 SANOFI US SERVICES INC. $1,680.00 07/28/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137621
Principal investigator 1 SANOFI US SERVICES INC. $1,970.76 07/28/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137624
Principal investigator 1 GlaxoSmithKline, LLC. $3,939.01 07/24/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192148076
Principal investigator 1 SANOFI US SERVICES INC. $80,985.80 07/14/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137575
Principal investigator 1 SANOFI US SERVICES INC. $4,954.43 07/14/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137605
Principal investigator 1 SANOFI US SERVICES INC. $170.00 07/02/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137579
Principal investigator 1 SANOFI US SERVICES INC. $19,443.87 07/02/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137613
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 06/26/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192146779
Principal investigator 1 SANOFI PASTEUR INC. $12,500.00 06/24/2025 Non-covered Recipient Entity
Kerlo Research
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226095672
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 06/09/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192146800
Principal investigator 1 SANOFI US SERVICES INC. $16,422.00 06/09/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137518
Principal investigator 1 GlaxoSmithKline, LLC. $410.00 06/03/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192148080
Principal investigator 1 SANOFI US SERVICES INC. $19,500.00 05/27/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137484
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 05/26/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192143034
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 05/26/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192144456
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 05/26/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192144477
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 05/14/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192146791
Principal investigator 1 SANOFI US SERVICES INC. $8,876.21 05/05/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137418
Principal investigator 1 SANOFI US SERVICES INC. $54,100.04 05/05/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137452
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 04/28/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192144465
Principal investigator 1 GlaxoSmithKline, LLC. $15,230.75 04/28/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192146783
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 03/06/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192146774
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 02/24/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192143005
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 02/24/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192144481
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 02/20/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192143024
Principal investigator 1 GlaxoSmithKline, LLC. $440.00 02/05/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192144469
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 02/05/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192148069
Principal investigator 1 GlaxoSmithKline, LLC. $420.00 02/03/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192144460
Principal investigator 1 GlaxoSmithKline, LLC. $16,127.50 01/28/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192146795
Principal investigator 1 GlaxoSmithKline, LLC. $700.00 01/07/2025 Non-covered Recipient Entity
NULINE CLINICAL TRIAL CENTER
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192148064